FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1509654317> ?p ?o ?g. }

• W1509654317 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAMacrophage migration inhibitory factor (MIF) is a proinflammatory cytokine with pleiotropic biologic effects and is pathologically associated with several types of cancer. oxMIF is an immunological and conformational distinct isoform of MIF that can be mimicked in vitro by mild oxidation of recombinant MIF. Fully human monoclonal antibodies that specifically target oxMIF were shown to inhibit downstream signaling pathways associated with tumor proliferation and progression in vitro and in vivo. We assessed the potential of anti-oxMIF antibodies combined with standard chemotherapeutic agents on the proliferation of cancer cell lines in vitro and in vivo in xenograft models. In vitro, anti-oxMIF sensitization of the prostate cancer cell lines PC3 or LnCAP significantly reduced the half maximal effective concentration (EC50) of mitoxantrone by 30% and 40%, respectively. In the ovarian cancer cell lines A2780, EC50 of cisplatin was reduced by 70% after sensitization with anti-oxMIF. In vivo, mice bearing pancreatic cancer xenografts (COLO357, BxPC3 or MiaPaCa2) treated with anti-oxMIF in combination with gemcitabine had a strong survival advantage compared with mice treated with either monotherapy. This effect was accompanied by a decrease of tumor volumes up to 70% and an increase in the expression of caspase 3 in mice bearing COLO357 xenografts. In addition, combining gemcitabine with anti-oxMIF treatment normalized blood vessel density inside the tumors, decreased their permeability by 25%, and decreased tumor VEGF levels by 40%, whereas gemcitabine alone had the opposite effect. In mice bearing the ovarian human cancer cell line A2780 xenografts, combining anti-oxMIF antibodies with cisplatin led to a 45% reduction of tumor weights. Anti-oxMIF specific antibodies decreased proliferation, angiogenesis and inflammation inside tumor xenografts, but were not cytotoxic (no antibody-dependent cell cytotoxicity or complement-dependent cytotoxicity). These experiments demonstrated synergistic effects between anti-oxMIF antibodies and cytotoxic chemotherapy. Combination treatments were superior to the corresponding monotherapies and led to a stronger inhibition of tumor growth and angiogenesis. A phase 1 clinical study of a novel human antibody that selectively targets oxMIF is currently ongoing in patients with solid malignancies (ClinicalTrials.gov identifier: [NCT01765790][1]).Citation Format: Patrice Douillard, Thorsten Hagemann, Michael Freissmuth, Michael Thiele, Alexander Schinagl, Dirk Volkel, Friedrich Scheiflinger, Randolf Kerschbaumer. Human antibodies specific for oxidized macrophage migration inhibitory factor (oxMIF) synergize with chemotherapeutic agents in animal models of cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2654. doi:10.1158/1538-7445.AM2014-2654 [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01765790&atom=%2Fcanres%2F74%2F19_Supplement%2F2654.atom" @default.
• W1509654317 created "2016-06-24" @default.
• W1509654317 creator A5012717738 @default.
• W1509654317 creator A5042240968 @default.
• W1509654317 creator A5045242452 @default.
• W1509654317 creator A5057826311 @default.
• W1509654317 creator A5060360807 @default.
• W1509654317 creator A5080659084 @default.
• W1509654317 creator A5089410333 @default.
• W1509654317 creator A5091504293 @default.
• W1509654317 date "2014-09-30" @default.
• W1509654317 modified "2023-09-26" @default.
• W1509654317 title "Abstract 2654: Human antibodies specific for oxidized macrophage migration inhibitory factor (oxMIF) synergize with chemotherapeutic agents in animal models of cancer" @default.
• W1509654317 doi "https://doi.org/10.1158/1538-7445.am2014-2654" @default.
• W1509654317 hasPublicationYear "2014" @default.
• W1509654317 type Work @default.
• W1509654317 sameAs 1509654317 @default.
• W1509654317 citedByCount "0" @default.
• W1509654317 crossrefType "proceedings-article" @default.
• W1509654317 hasAuthorship W1509654317A5012717738 @default.
• W1509654317 hasAuthorship W1509654317A5042240968 @default.
• W1509654317 hasAuthorship W1509654317A5045242452 @default.
• W1509654317 hasAuthorship W1509654317A5057826311 @default.
• W1509654317 hasAuthorship W1509654317A5060360807 @default.
• W1509654317 hasAuthorship W1509654317A5080659084 @default.
• W1509654317 hasAuthorship W1509654317A5089410333 @default.
• W1509654317 hasAuthorship W1509654317A5091504293 @default.
• W1509654317 hasConcept C104177226 @default.
• W1509654317 hasConcept C121608353 @default.
• W1509654317 hasConcept C126322002 @default.
• W1509654317 hasConcept C150903083 @default.
• W1509654317 hasConcept C203014093 @default.
• W1509654317 hasConcept C207001950 @default.
• W1509654317 hasConcept C2776694085 @default.
• W1509654317 hasConcept C2778239845 @default.
• W1509654317 hasConcept C2778690821 @default.
• W1509654317 hasConcept C2779723316 @default.
• W1509654317 hasConcept C2780258809 @default.
• W1509654317 hasConcept C2780427987 @default.
• W1509654317 hasConcept C502942594 @default.
• W1509654317 hasConcept C71924100 @default.
• W1509654317 hasConcept C86803240 @default.
• W1509654317 hasConcept C96232424 @default.
• W1509654317 hasConcept C98274493 @default.
• W1509654317 hasConceptScore W1509654317C104177226 @default.
• W1509654317 hasConceptScore W1509654317C121608353 @default.
• W1509654317 hasConceptScore W1509654317C126322002 @default.
• W1509654317 hasConceptScore W1509654317C150903083 @default.
• W1509654317 hasConceptScore W1509654317C203014093 @default.
• W1509654317 hasConceptScore W1509654317C207001950 @default.
• W1509654317 hasConceptScore W1509654317C2776694085 @default.
• W1509654317 hasConceptScore W1509654317C2778239845 @default.
• W1509654317 hasConceptScore W1509654317C2778690821 @default.
• W1509654317 hasConceptScore W1509654317C2779723316 @default.
• W1509654317 hasConceptScore W1509654317C2780258809 @default.
• W1509654317 hasConceptScore W1509654317C2780427987 @default.
• W1509654317 hasConceptScore W1509654317C502942594 @default.
• W1509654317 hasConceptScore W1509654317C71924100 @default.
• W1509654317 hasConceptScore W1509654317C86803240 @default.
• W1509654317 hasConceptScore W1509654317C96232424 @default.
• W1509654317 hasConceptScore W1509654317C98274493 @default.
• W1509654317 hasLocation W15096543171 @default.
• W1509654317 hasOpenAccess W1509654317 @default.
• W1509654317 hasPrimaryLocation W15096543171 @default.
• W1509654317 hasRelatedWork W2003126314 @default.
• W1509654317 hasRelatedWork W2035328939 @default.
• W1509654317 hasRelatedWork W2049804579 @default.
• W1509654317 hasRelatedWork W2055578912 @default.
• W1509654317 hasRelatedWork W2088876286 @default.
• W1509654317 hasRelatedWork W2127086398 @default.
• W1509654317 hasRelatedWork W2135929809 @default.
• W1509654317 hasRelatedWork W2153534791 @default.
• W1509654317 hasRelatedWork W2314353439 @default.
• W1509654317 hasRelatedWork W2317478260 @default.
• W1509654317 hasRelatedWork W2326728180 @default.
• W1509654317 hasRelatedWork W2411779230 @default.
• W1509654317 hasRelatedWork W2885785527 @default.
• W1509654317 hasRelatedWork W2953841434 @default.
• W1509654317 hasRelatedWork W2961234104 @default.
• W1509654317 hasRelatedWork W3010772258 @default.
• W1509654317 hasRelatedWork W3083361780 @default.
• W1509654317 hasRelatedWork W3180207529 @default.
• W1509654317 hasRelatedWork W2777597725 @default.
• W1509654317 hasRelatedWork W2887385779 @default.
• W1509654317 isParatext "false" @default.
• W1509654317 isRetracted "false" @default.
• W1509654317 magId "1509654317" @default.
• W1509654317 workType "article" @default.